Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD-1: Short vs Standard Anti-HER2 Treatment in Early Breast Cancer
NCT02625441Phase 3Active, not recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2015
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in HER2-positive breast cancer, sponsored by Helsinki University Hospital. Started Dec 2015; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02625441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625441.